Logo

Apollomics Reports First Patient Dosing in P-III Clinical Trial of Uproleselan for the Treatment of AML

Share this

Apollomics Reports First Patient Dosing in P-III Clinical Trial of Uproleselan for the Treatment of AML

Shots:

  • The first patient has been dosed in a P-III clinical trial to evaluate the efficacy of uproleselan + CT vs CT alone in 140 adult patients with r/r AML and who are eligible to receive induction CT at ~20 blood cancer clinical research centers across China. The therapy is discovered and developed by GlycoMimetics
  • The 1EPs of the study is OS and secondary outcomes include the rate and duration of remission, and reduce the rate of oral mucositis
  • Uproleselan is the E-selectin-targeted inhibitor & has received BTD from the US FDA and NMPA for AML patients. Additionally, Apollomics gets the rights for uproleselan from GlycoMimetics in Greater China

Click here to­ read full press release/ article 

Ref: Businesswire | Image: Apollomics 


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions